Cytokinetics Financial Ratios
NASDAQ: CYTKHealth CareBiotechnology: Pharmaceutical PreparationsUSD
62.91+0.90 (+1.45%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Cytokinetics ratio analysis
Cytokinetics earned a net margin of -891.6% in FY 2025, up from -3191.1% a year earlier. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Cytokinetics financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | — | — | — | — | — | — | — | — | — | 31.15 |
| Price / sales | 0.08 | 0.30 | 1.07 | 0.04 | 0.05 | 0.02 | 0.02 | 0.01 | 30.12 | 4.56 |
| Price / book | — | — | — | — | 0.01 | 0.01 | — | 0.02 | 3.67 | 5.14 |
| Operating margin | -695.4% | -2,902.7% | -6,589.7% | -342.8% | -264.5% | -168.3% | -368.0% | -282.3% | -848.3% | 17.6% |
| Net margin | -891.6% | -3,191.1% | -6,988.6% | -411.2% | -305.7% | -228.0% | -452.9% | -337.4% | -955.9% | 15.5% |
| Free cash flow margin | -607.5% | -2,164.1% | -5,521.2% | -328.6% | -271.8% | -3.8% | -348.1% | -324.1% | -782.7% | 33.3% |
| Return on equity (ROE) | — | — | — | — | -88.3% | -112.3% | — | -409.8% | -116.3% | 17.4% |
| Return on assets (ROA) | -55.1% | -42.1% | -63.8% | -38.3% | -25.6% | -23.8% | -42.0% | -50.3% | -43.3% | 9.7% |
| Debt / equity | — | — | — | — | 0.19 | 0.41 | — | 1.64 | 0.29 | 0.32 |
| Current ratio | 4.53 | 6.17 | 6.12 | 9.40 | 7.45 | 15.20 | 8.98 | 9.36 | 8.45 | 4.77 |
| Revenue growth | 376.6% | 145.3% | -92.0% | 34.3% | 26.2% | 107.8% | -14.7% | 135.6% | -87.4% | 271.3% |
| EPS growth | — | — | — | — | — | — | — | — | -764.1% | — |